KDIGO has made the new “Clinical Practice Guideline for Acute Kidney Injury (AKI) and Acute Kidney Disease (AKD)” 2026 available for public review, marking an important step in the evolution of AKI management. The document represents the first substantial update to the guidelines published in 2012 and presents a broader and more advanced approach to Acute Kidney Injury, covering definition, identification, classification, diagnostic evaluation, prevention, treatment, and renal replacement therapy.
The draft clearly highlights a paradigm shift: AKI is no longer considered only as an event to be recognized once kidney damage is already clinically evident, but as a condition in which early intervention, based on risk assessment, can significantly influence the patient’s clinical course.
One of the most relevant updates concerns risk stratification. The document describes a structured approach in which individual susceptibilities, exposures, clinical scoring systems, biomarkers, and risk prediction models contribute to stratifying patients according to their likelihood of developing AKI or related outcomes. In this context, the concepts of proactive personalized AKI prevention, early recognition, and individualized management are explicitly mentioned, confirming the growing integration of proactive and personalized strategies into clinical practice.
A particularly distinctive element of the draft is the explicit and reinforced recognition of the value of AKI risk prediction models, especially when externally validated. The guideline highlights their role not only as support tools, but also as enabling components of a more anticipatory and systematic clinical approach. In particular, KDIGO indicates that externally validated clinical risk models can:
- improve the early identification of children and adults at increased risk of AKI, before clinically evident injury occurs;
- guide the timely implementation of prevention and kidney protection strategies;
- support the identification of adults at risk of receiving renal replacement therapy for AKI, enabling more informed clinical decisions, shared decision making, and more effective care planning;
- contribute to more consistent and objective risk stratification within clinical pathways.
This positioning marks an important shift: predictive models are recognized as key tools to translate a more proactive, personalized, and data driven approach to AKI management into clinical practice.
For U-Care Medical, this evolution is particularly significant. The document highlights how risk stratification and early identification of AKI are becoming central elements of clinical practice, reinforcing the value of approaches that support more timely decisions and targeted preventive interventions. From this perspective, the relevance of solutions designed to enable earlier, concrete, and clinically meaningful AKI prevention, such as the U-Care Renal Platform, is further strengthened.
AKI management is therefore evolving towards a model in which risk anticipation plays a key role. The KDIGO 2026 draft consolidates this direction, highlighting the value of an earlier, more structured, and prevention oriented approach.